Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab + Cabozantinib vs Docetaxel in previously treated metastatic NSCLC
NCT04471428Phase 3Completed
- Sponsor
- Roche
- Start
- Oct 2020
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 15
01
Overview
A Phase 3 trial of cabozantinib in non-small cell lung cancer (NSCLC), sponsored by Roche. Started Oct 2020; status: completed.
02
Drugs
cabozantinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04471428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04471428.